Dynavax Announces First Quarter 2019 Financial Results
First quarter 2019 HEPLISAV-B® net product revenue of $5.6 million Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT BERKELEY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated …